Trifarotene Aklief denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for trifarotene aklief are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Trifarotene (Aklief) as Not Medically Necessary

Aklief (trifarotene) is a topical retinoid for acne vulgaris. Aetna's medical-necessity denials for this drug most often occur because the submitted documentation did not sufficiently establish the severity of the acne, the failure of less expensive alternatives (such as generic tretinoin or adapalene), or the clinical rationale for choosing a newer branded retinoid over existing options. In many cases, the clinical evidence is in the chart — it simply was not included in the prior authorization submission.

## Why This Denial Is Appealable

Medical necessity is a clinical judgment, and insurers are required to base their determinations on evidence-based criteria. If your dermatologist has documented disease severity, treatment history, and the clinical reasoning for trifarotene, an appeal supported by that documentation has a strong likelihood of success. Aetna must demonstrate that its criteria are grounded in recognized clinical standards, and your physician's documented judgment carries significant weight.

## Your Federal Appeal Rights

• Internal appeal: File within the timeframe on your EOB. A robust clinical package — not just a resubmission of the original PA — is essential.
• External review (ACA §2719): If the internal appeal is denied, an independent IRO reviews the clinical record on its merits, typically within about four months of the original denial. The IRO is not bound by Aetna's internal policies.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review with access to all documents, criteria, and clinical reviewers' notes used in the determination.
• Expedited review: Available when the denial is causing or will imminently cause significant health deterioration.

## Documentation to Gather

• Diagnosis and severity documentation: Chart notes from your dermatologist confirming the acne diagnosis and documenting clinical severity — including affected body areas, lesion type and count as recorded in the chart, and psychosocial impact if documented.
• Prior treatment history: A complete record of every topical and oral acne treatment previously tried, with start/end dates, adherence, and documented outcomes (inadequate clearance, tolerability issues, or contraindications).
• Prescriber medical-necessity letter: Your dermatologist should explain specifically why trifarotene is the appropriate next step, why prior agents were insufficient, and reference the applicable American Academy of Dermatology (AAD) guideline direction — without citing specific numerical thresholds from it.
• Aetna's medical-necessity criteria: Request the exact criteria Aetna applied; you are entitled to this under ERISA or state law.

## Criteria-Mapping Structure

Obtain Aetna's medical-necessity criteria for topical retinoids. Map each criterion to your chart:

| Aetna Criterion | Chart Evidence | Document Reference | |---|---|---| | Diagnosis confirmed | Dermatologist note confirming acne vulgaris | Chart note [date] | | Severity documented | Clinical description in chart | Chart note [date] | | Prior therapy tried and failed | Medication history with outcomes | Medication list + chart notes | | Prescriber supports medical necessity | Letter of medical necessity | Attached as Exhibit A |

This structured mapping gives Aetna's appeal reviewer a direct path to reversal without requiring them to reconstruct your clinical history from a narrative alone.